1248667-63-1

Basic information

• Product Name: 1-(p-tolylcarbamoyl)cyclopropane-1-carboxylic acid
• Synonyms: 1-(p-tolylcarbamoyl)cyclopropane-1-carboxylic acid
• CAS NO: 1248667-63-1
• Molecular Weight: 219.24
• Mol File: 1248667-63-1.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 1-(p-tolylcarbamoyl)cyclopropane-1-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(p-tolylcarbamoyl)cyclopropane-1-carboxylic acid(1248667-63-1)
• EPA Substance Registry System: 1-(p-tolylcarbamoyl)cyclopropane-1-carboxylic acid(1248667-63-1)

Safety Data

• Hazardous Substances Data: 1248667-63-1(Hazardous Substances Data)

Upstream product

• 598-10-7 cyclopropane-1,1-dicarboxylic acid 
• 106-49-0 p-toluidine 
• 1373611-14-3 methyl 1-(p-tolylcarbamoyl)cyclopropane-1-carboxylate 
• 113020-21-6 1,1-cyclopropanedicarboxylic acid monomethyl ester 
• 6914-71-2 dimethyl 1,1-cyclopropanedicarboxylate 
• 40258-99-9 1-(chlorocarbonyl)cyclopropane-1-carboxylic acid 

Downstream Products

• 1584219-78-2 N-(4-((2-((3-((methylsulfonyl)methyl)phenyl)amino)pyrimidin-4-yl)oxy)phenyl)-N'-(p-tolyl)cyclopropane-1,1-dicarboxamide 

Relevant articles and documents

Novel dual inhibitors targeting CDK4 and VEGFR2 synergistically suppressed cancer progression and angiogenesis

Based on the significantly synergistic effects of CDK4 and VEGFR2 inhibitors on growth of cancer cells, a series of novel multi-kinase inhibitors targeting CDK4 and VEGFR2 were designed, synthesized and evaluated, among which Roxyl-ZV-5J exhibited potent and balanced activities against both CDK4 and VEGFR2 with half-maximal inhibitory concentration at the nanomolar level. It effectively induced breast and cervical cancer cell cycle arrest and cell apoptosis. Roxyl-ZV-5J also inhibited the proliferation, tube formation and VEGFR2 downstream signaling pathways of HUVECs. Oral administration of Roxyl-ZV-5J led to significant tumor regression and anti-angiogenesis without obvious toxicity in SiHa xenograft mouse model. In addition, this compound showed good pharmacokinetics. This study confirmed a new tool for dual CDK-VEGFR2 pathways inhibition achieved with a single molecule, which provided valuable leads for further structural optimization and anti-angiogenesis and anti-tumor mechanism study.

Discovery of a highly potent, selective and novel CDK9 inhibitor as an anticancer drug candidate

A series of novel hybrid structure derivatives, containing both LEE011 and Cabozantinib pharmacophore, were designed, synthesized and evaluated. Surprisingly, a compound 4d was discovered that highly exhibited effective and selective activity of CDK9 inhi

Discovery of anilinopyrimidines as dual inhibitors of c-Met and VEGFR-2: Synthesis, SAR, and cellular activity

Both c-Met and VEGFR-2 are important targets for cancer therapies. Here we report a series of potent dual c-Met and VEGFR-2 inhibitors bearing an anilinopyrimidine scaffold. Two novel synthetic protocols were employed for rapid analoguing of the designed